|
Mean age, yr (SD)
|
46.2 (11.8)
|
41.9 (14.3)
|
58.7 (14.5)
|
|
Females, n (%)
|
15 (78.9)
|
46 (71.9)
|
11 (55.0)
|
|
Positive family history of RA, n (%)
|
N/A
|
25 (39.1)
|
4 (20.0)
|
|
Median symptom duration at time of inclusion, wk (IQR)
|
N/A
|
13.4 (8.4 to 26.4)
|
17.6 (11.5 to 25.9)
|
|
Gradual symptom onset, n (%)
|
N/A
|
48 (75.0)
|
12 (60.0)
|
|
Initial symptom localization, n (%)
|
N/A
| | |
|
Upper extremities, n (%)
| |
47 (73.4)
|
10 (50.0)
|
|
Lower extremities, n (%)
| |
2 (3.1)
|
4 (20.0)
|
|
Upper and lower extremities, n (%)
| |
15 (23.4)
|
6 (30.0)
|
|
Symmetrical localization, n (%)
|
N/A
|
46 (71.9)
|
13 (65.0)
|
|
Median morning stiffness, min (IQR)
|
N/A
|
45 (15 to 90)
|
120 (30 to 120)
|
|
Median tender joint count in 68 joints (IQR)
|
0
|
5.5 (3 to 10.8)
|
12 (4.8 to 17.8)
|
|
Median swollen joint count 66 joints (IQR)
|
0
|
0
|
6 (4 to 11)
|
|
ACPA positivity (>7.0 IU/ml), n (%)
|
N/A
|
0
|
0
|
|
IgM RF positivity (>3.5 IU/ml), n (%)
|
N/A
|
9 (14.1)
|
3 (15.0)
|
|
Increased CRP level (>10 mg/L), n (%)
|
N/A
|
10 (15.6)
|
11 (55.0)
|
